Table One.
Incidence rate (IR)£ and incidence rate ratio (IRR)Ω of oropharyngeal squamous cell cancer (OPSCC) and non-oropharyngeal head and neck squamous cell cancer per 100,000, by sex, age, and race from 1992–2014. Average APC (aAPC)¥ also shown.
| All HNSCC | OPSCC | Non-oropharyngeal HNSCC | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Incidence rate per 100,000 (95% CI) |
IRR | aAPC p-value |
Incidence rate per 100,000 (95% CI) |
IRR | aAPC, p-value |
Incidence rate per 100,000 (95% CI) |
IRR | aAPC, p-value |
|
|
| |||||||||
| Overall | 11.2 (11.1–11.3) | −0.8, p<.001 | 3.4 (3.4–3.5) | 1.2, p<.001 | 7.8 (7.7–7.8) | −1.6, p<.001 | |||
|
| |||||||||
| Sex | |||||||||
| Women | 5.5 (5.5–5.6) | Reference | −1.2, p<.001 | 1.4 (1.3–1.4) | Reference | −0.8, p=.002 | 4.1 (4.1–4.2) | Reference | −1.0, p=.003 |
| Men | 17.9 (17.8–18.0) | 3.2 | −0.8, p<.001 | 5.8 (5.7–5.9) | 4.2 | 1.7, p<.001 | 12.1 (12.0–12.2) | 2.9 | −2.0, p<.001 |
|
| |||||||||
| Age | |||||||||
| < 30 | 0.1(0.1–0.1) | 0.0 | 0.04, p=.95 | 0.0 (0.0–0.0) | 0.0 | - | 0.1 (0.1–0.1) | 0.0 | −0.1, p=.89 |
| 30–39 | 1.5 (1.4–1.5) | 0.1 | −0.7, p=.02 | 0.3 (0.3–0.4) | 0.0 | −0.3, p=.70 | 1.1 (1.1–1.2) | 0.1 | −0.8, p=.02 |
| 40–49 | 7.7 (7.6–7.9) | 0.3 | −1.0, p<.001 | 3.1 (3.0–3.1) | 0.3 | 0.5, p=.17 | 4.7 (4.6–4.8) | 0.3 | −2.0. p<.001 |
| 50–59 | 23.9 (23.6–24.2) | Reference | −0.6, p<.001 | 9.3 (9.1–9.5) | Reference | 2.0, p<.001 | 14.6 (14.3–14.8) | Reference | −2.0, p<.001 |
| 60–69 | 41.5 (41.1–42.0) | 1.7 | −1.1, p<.001 | 13.4 (13.1–13.6) | 1.4 | 1.5, p<.001 | 28.2 (27.8–28.6) | 1.9 | −2.4, p<.001 |
| 70–79 | 47.0 (46.3–47.6) | 2.0 | −1.0, p<.001 | 11.4 (11.1–11.7) | 1.2 | 1.4, p=.29 | 35.6 (35.0–36.1) | 2.4 | −1.9, p=.02 |
| ≥80 | 38.5 (37.8–39.2) | 1.6 | −0.02, p=.90 | 7.0 (6.7–7.3) | 0.7 | 0.7, p=.10 | 31.5 (30.9–32.2) | 2.2 | −0.2, p=.12 |
|
| |||||||||
| Race/ethnicity | |||||||||
| White NH* | 12.2 (12.1–12.3) | Reference | −0.2, p=.02 | 4.0 (3.9–4.0) | Reference | 2.0, p<.001 | 8.2 (8.2–8.3) | Reference | −1.4, p<.001 |
| Black NH | 14.3 (14.0–14.5) | 1.2 | −2.8, p<.001 | 4.4(4.3–4.6) | 1.1 | −1.8, p<.001 | 9.8 (9.6–10.1) | 1.2 | −3.3, p<.001 |
| Hispanic | 7.2 (7.0–7.4) | 0.6 | −0.9, p=.04 | 1.9 (1.8–2.0) | 0.5 | 1.0, p=.13 | 5.3 (5.1–5.4) | 0.6 | −1.5, p<.001 |
| Asian NH | 6.8 (6.6–6.9) | 0.6 | −1.3, p=.01 | 1.2 (1.2–1.3) | 0.3 | −0.3, p=.63 | 5.5 (5.4–5.7) | 0.7 | −1.1, p=.11 |
| AIAN NH | 8.6 (7.9–9.3) | 0.7 | 0.5, p=.24 | 2.4 (2.1–2.8) | 0.6 | - | 6.2 (5.6–6.8) | 0.7 | - |
|
| |||||||||
| Calendar Period | |||||||||
| 1992–1999 | 12.2 (12.1–12.3) | Reference | −1.6, p<.001 | 3.1 (3.0–3.2) | Reference | −0.3, p=.55 | 9.1 (9.0–9.2) | Reference | −2.0, p<.001 |
| 2000–2009 | 10.7 (10.6–10.8) | 0.9, p<.001 | −0.49, p=.24 | 3.4 (3.3–3.4) | 1.1 p<.001 | 2.3, p<.001 | 7.4 (7.3–7.4) | 0.8 p<.001 | −1.7, p<.001 |
| 2010–2014 | 10.8 (10.6–10.9) | 0.9, p<.001 | −0.1, p=.73 | 3.9 (3.8–4.0) | 1.3 p<.001 | 2.6, p=.02 | 6.9 (6.8–7.0) | 0.8 p<.001 | −1.6, p=.009 |
Non-Hispanic
An incidence rate (IR) is the risk of a specified diagnosis, calculated as the number of new diagnoses per 100,000 people in the specific sex, age or race group who do not previously have this diagnosis) during the time period of interest. For example, an IR of 10 signifies for each 100,000 people without HNSCC, 10 were diagnosed with HNSCC during the time period of 1992–2014. The IR in this table were age-adjusted to the 2000 US Standard Population (19 age groups – Census P25-1130), providing a population-based estimate for the rate of diagnosis.
Incidence rate ratios (IRR) compare risk between variables. For example, IRR of 3.2 for men indicates that the incidence rate was 3.2 times higher among men than women during the time period.
Average annual percent change (aAPC) provides an estimate of the change in the rate of diagnosis during that time period. A significant aAPC indicates an increase (>0) or decrease (<0) in incidence (risk) during the time period, while a non-significant aAPC indicates that incidence rates were stable during that time period.